Overview
- During the second RTL election debate, Frans Timmermans accused D66 leader Rob Jetten of lying about not freezing access to new, reimbursed treatments.
- CPB modelling shows D66 told the bureau it would halt additions to the basic package, with projected savings of about €500 million in 2030 and up to €7.7 billion over the long term.
- D66 maintains its plan would allow one‑for‑one replacement of ineffective care with new therapies, a policy nuance the CPB framework does not capture.
- The CPB warns a freeze would block reimbursement of new, costly treatments and could slow improvements in care quality, while sector experts question whether a strict freeze is achievable.
- Patient voices and the Patients Federation issued urgent warnings that such plans risk shutting out proven innovations, highlighting cases like a rare ovarian cancer patient dependent on new options.